Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
 |
Results for 'Pipeline and Commercial Insight: Alzheimer's Disease' |
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
|
Pipeline and Commercial Insight: Alzheimer's Disease Scenario Forecasts Reveal Vast Market Potential |
March 2008 | £5020 | 100 % |
|
Pipeline And Commercial Insight: Parkinson's Disease Market To Grow As First Round Of Lifecycle Management Strategies Succeed |
September 2007 | £5020 | 72 % |
|
Commercial and Pipeline Insight: Inflammatory Bowel Disease Competition Increases for the Biologics |
November 2006 | £3965 | 71 % |
|
Multiple Myeloma - Exploring New Targets For Multiple Drug Therapy Stakeholder Opinions |
December 2007 | £1320 | 35 % |
|
Stakeholder Insight: Alzheimer's Disease Prescribing trends indicate that neurologists are not adhering to guidelines |
December 2006 | £5285 | 33.95 % |
|
Stakeholder Opinions: Cystic Fibrosis |
March 2006 | £1450 | 31.5 % |
|
Stakeholder Opinions: Head and Neck Cancer Innovatives to Change the Face of Treatment |
November 2007 | £1325 | 30.5 % |
|
Stakeholder Opinions: Respiratory Syncytial Virus (RSV) A market yet to reach its full potential |
December 2006 | £1325 | 29.5 % |
|
Stakeholder Opinions Respiratory Syncytial Virus (RSV) A market yet to reach its full potential |
January 2007 | £1320 | 29.5 % |
|
Pipeline Insight: Parkinson's Disease and Restless Legs Syndrome Reformulations set to drive near-term growth |
August 2006 | £5745 | 28.5 % |
|
Pipeline Insight: Orphan Diseases in CNS - Part I: Huntington's Disease |
November 2007 | £2510 | 28.35 % |
|
Stakeholder Opinions: Bladder Cancer New drugs needed to challenge ineffective 20 year old drugs |
November 2008 | £1320 | 28 % |
|
Stakeholder Opinions: Melanoma Lucrative commercial opportunities persist |
December 2006 | £1320 | 27.5 % |
|
Commercial Insight Antithrombotics Pipeline products to dampen the impact of patent expiries and cost containment initiatives |
February 2007 | £5285 | 27.3 % |
|
Stakeholder Opinions: Biologics in Infectious Diseases Well Defined Target Populations Are Key to Commercial Success |
March 2008 | £1320 | 26.95 % |
|
Pipeline Insight: Colorectal Cancer Growing trend towards personalized medicine |
October 2009 | £7530 | 25.55 % |
|
Pipeline Insight: Orphan Diseases in Neurology Part III: Myasthenia Gravis |
November 2008 | £3965 | 24.5 % |
|
Pipeline Insight: Therapeutic Cancer Vaccines A turbulent path from bench to bedside |
December 2006 | £3965 | 24.15 % |
|
Stakeholder Opinions: Osteoarthritis Preconceptions Damage Awareness and Treatments |
March 2006 | £1450 | 23 % |
|
Stakeholder Perspectives: Pulmonary Arterial Hypertension A small market gets big attention |
February 2006 | £2875 | 22 % |
|
Colorectal Cancer: Pipeline/Commercial Insight Shaping the future dynamics of colorectal cancer management |
October 2006 | £5285 | 21.35 % |
|
Stakeholder Opinions: Pulmonary Arterial Hypertension clinical community builds order from chaos Healthcare |
March 2009 | £1320 | 21.35 % |
|
Stakeholder Opinions: Bone Metastases Impending Patent Expiries May Help Make or Break Newer Agents |
March 2008 | £1320 | 21 % |
|
Stakeholder Opinions: Systemic Lupus Erythematosus Market Set to Enter Era of Biologic Therapies |
March 2008 | £1355 | 19.95 % |
|
Pipeline Insight: Breast Cancer Recent approvals increase pressure on pipeline candidates |
April 2008 | £3965 | 19.6 % |
|
Commercial and Pipeline Insight Vaccines for Adults and The Elderly - New Blockbuster Opportunities Ahead |
July 2008 | £5085 | 18.55 % |
|
Pipeline Insight: Nosocomial Vaccines Minefield or Goldmine? |
April 2008 | £3965 | 18.55 % |
|
Commercial and Pipeline Insight Vaccines for Adults and The Elderly - New Blockbuster Opportunities Ahead |
July 2008 | £5085 | 18.55 % |
|
Commercial and Pipeline Insight: ADHD Immature adult market continues to offer greatest commercial potential |
April 2008 | £5285 | 18.2 % |
|
Pipeline and Commercial Insight: Osteoporosis Novel agents to battle for payer acceptance |
July 2009 | £10040 | 18.2 % |
|
Innovations in Cancer Novel Therapeutics, New Diagnostics and Future R&D Strategies |
February 2007 | £1495 | 18 % |
|
Novartis AG: PharmaVitae Profile |
July 2009 | £3765 | 17.85 % |
|
Pipeline Insight: Acute Stroke Commercial Risk Offsets High Unmet Need |
May 2008 | £3965 | 17.85 % |
|
Commercial and Pipeline Insight: Psoriasis Anti-TNF's lead another indication |
December 2006 | £5285 | 17.5 % |
|
Lymphoma A Therapeutic & Competitive Insight |
May 2006 | £1745 | 16.5 % |
|
Triple Progress Analysis: Melanoma, Colorectal & Lung Cancer |
March 2006 | £3090 | 16.5 % |
|
Stakeholder Opinions: Gynecological Cancers Niche opportunities in advanced disease |
December 2006 | £1325 | 16.45 % |
|
Stakeholder Opinions: Fibromyalgia Potentially lucrative market soon to become reality |
May 2007 | £1325 | 16.1 % |
|
Pipeline Insight: Non-Small Cell Lung Cancer Pipeline set to offer only modest improvements |
April 2008 | £3965 | 16.1 % |
|
Commercial Insight: Multiple Sclerosis Continued growth makes the MS market a highly attractive investment |
June 2007 | £5020 | 15.75 % |
|
Pipeline Insight: Epilepsy Pipeline drugs struggle to outshine their marketed predecessors |
October 2006 | £3965 | 15.05 % |
|
Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents |
October 2006 | £3090 | 15 % |
|
Pipeline Insight: Osteoarthritis The Wait for a DMOAD Continues |
November 2006 | £3965 | 14.7 % |
|
Pipeline and Commercial Insight: Obesity - the $11 billion market that never was |
July 2009 | £10040 | 14.7 % |
|
Current and Future Therapies for Lung Cancer A Therapeutic & Competitive Insight |
March 2006 | £1745 | 14.5 % |
|
Commercial and Pipeline Insight: Hepatitis B |
October 2007 | £5020 | 14.35 % |
|
Pipeline/Commercial Insight: Antihypertensives New class opportunity offset by key patent expiries |
July 2007 | £5020 | 14 % |
|
Forecast Insight: Opioids - Saturation limits the commercial potential of individual brands Healthcare |
March 2009 | £5285 | 14 % |
|
Tumour Markers Clinical Trial Analysis |
July 2009 | £660 | 14 % |
|
Targeted Therapeutics in Non-Small Cell Lung Cancer |
April 2007 | £1400 | 14 % |
|
Pipeline Insight: Hepatitis C Protease inhibitors to drive market expansion |
June 2006 | £4290 | 13.65 % |
|
Stakeholder Opinions: Tuberculosis - Development pipeline shows signs of life Healthcare |
March 2009 | £1320 | 13.3 % |
|
Pipeline Insight: Hematological Malignancies Companies target niche indications to facilitate market entry |
April 2009 | £3965 | 12.95 % |
|
Multiplex Assays in Translational Medicine Technologies, Applications, and Future Directions |
February 2008 | £745 | 12.6 % |
|
Antiageing and Life Enhancement Pharmacotherapeutics |
January 2006 | £795 | 12.5 % |
|
Hematological Cancers - A Therapeutic & Competitive Insight |
October 2006 | £2645 | 12.5 % |
|
Commercial Insight: Pain Market Overview Non-Traditional Analgesics and Opioid Reformulations to Sustain Sector Growth |
October 2008 | £5285 | 12.25 % |
|
Abbott Laboratories: PharmaVitae Profile Healthcare |
September 2009 | £3765 | 11.9 % |
|
Pipeline/Commercial Insight: Supportive Care in Oncology Significant growth opportunities exist in new supportive care indications |
June 2007 | £5020 | 11.9 % |
|
Commercial Insight: Neuropathic Pain A Plethora of Patient Segmentation and Product Differentiation Opportunities |
July 2006 | £5575 | 11.2 % |
|
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies More drugs on the market, more targets in the pipeline |
October 2006 | £5285 | 10.85 % |
|
Pipeline and Commercial Insight: Anxiety Disorders Viable indication for antipsychotics companies |
November 2008 | £5285 | 10.85 % |
|
Commercial and Pipeline Insight: Systemic antifungals |
November 2007 | £5020 | 10.5 % |
|
Pipeline Insight: Molecular Targeted Cancer Therapies More pipeline activity, less product differentiation |
November 2008 | £5285 | 10.5 % |
|
Commercial Insight: Antihypertensives New challenges for a maturing market |
September 2006 | £5285 | 9.45 % |
|
Pipeline and Commercial Insight: Nicotine Dependence - Chantix issues overshadow vaccine potential Healthcare |
March 2009 | £5285 | 8.4 % |
|
Commercial Insight: Asthma & COPD Combination Products Still Have Blockbuster Potential |
July 2007 | £5020 | 8.05 % |
